A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

The shift reflects more than a funding gap - it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble ...

MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® ...

Tumors are heterogenous masses of cells that rapidly divide. Many cells have different mutations, functions, and ways to ...

Program highlights for the fiscal year ended March 31, 2025, along with recent developments, include: Patient with advanced/metastatic end-stage pancreatic cancer who responded to MDNA11 treatment ...

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

In March, Senhwa made the strategic decision to discontinue its Community-Acquired Pneumonia clinical trial, prompting investor concern. This shift, based on compelling interim findings, redirected ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...